The FDA Class 1 review with a 6-week PDUFA date (July 29) is a strong positive signal that the resubmission is complete and reviewable. Traders should watch for potential FDA decision by late July; a positive outcome could drive significant upside given the first-to-market positioning and existing EU/UK approvals. Monitor for any FDA briefing documents or AdCom announcements in the interim.
Price Chart
Executive Summary
Outlook Therapeutics announced FDA acceptance of its resubmitted BLA for ONS-5010/LYTENAVA (bevacizumab-vikg) for wet AMD as a Class 1 review with a PDUFA target date of July 29, 2026. The company has initiated pre-launch activities, and approval would make it the first FDA-approved ophthalmic formulation of bevacizumab with standardized manufacturing and labeling. This is a major regulatory milestone for a $162M market-cap biotech with a single primary asset.
Key Facts
- FDA accepted resubmitted BLA for ONS-5010/LYTENAVA as Class 1 review
- PDUFA target action date set for July 29, 2026
- ONS-5010/LYTENAVA already has EU and UK marketing authorization for wet AMD
- Company has initiated pre-launch activities in anticipation of potential approval
- First and only FDA-approved ophthalmic formulation of bevacizumab would be a novel product
Financial Impact
Potential US market approval for first ophthalmic bevacizumab; no financial figures provided in release
Risk Factors
- FDA may issue a Complete Response Letter (CRL) despite Class 1 acceptance
- Manufacturing or labeling issues could delay or prevent approval
- Competition from existing anti-VEGF therapies (e.g., Eylea, Lucentis, Vabysmo) may limit market share
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3312535 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | 424B5 | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | Press Release | $0.7564 $0.6379 | ▼ −15.67% | ▼ −13.67% | $0.5778 (−23.61%) |
Aug 13, 2026 7w ago | Press Release | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5778 (+34.99%) |
Aug 12, 2026 7w ago | 8-K | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5778 (+34.99%) |
Jul 24, 2026 9w ago | 8-K | $1.07 $0.6090 | ▼ −42.82% | ▼ −46.12% | $0.5778 (−45.75%) |
Jul 24, 2026 10w ago | Press Release | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5778 (−58.88%) |
Jul 23, 2026 10w ago | 8-K | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5778 (−58.88%) |
Jul 22, 2026 10w ago | EFFECT | $1.34 $0.6901 | ▼ −48.50% | ▼ −51.40% | $0.5778 (−56.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access